ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
1.510
+0.050 (3.42%)
At close: Dec 20, 2024, 4:00 PM
1.624
+0.114 (7.54%)
After-hours: Dec 20, 2024, 7:01 PM EST
ProKidney Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
163
Market Cap
440.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 1.13B |
| Sonida Senior Living | 253.20M |
| Treace Medical Concepts | 202.86M |
| UroGen Pharma | 89.36M |
| Personalis | 87.49M |
| Codexis | 64.45M |
| AnaptysBio | 57.17M |
| OmniAb | 20.41M |
PROK News
- 25 days ago - ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting - GlobeNewsWire
- 6 weeks ago - ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference - GlobeNewsWire
- 2 months ago - ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 - GlobeNewsWire
- 2 months ago - ProKidney to Participate in the UBS Virtual Organ Restoration Day - GlobeNewsWire
- 3 months ago - ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. - GlobeNewsWire
- 4 months ago - ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire
- 4 months ago - ProKidney Reports Business Updates and Second Quarter 2024 Financial Results - GlobeNewsWire